Alladapt Immunotherapeutics, Inc.

Alladapt Immunotherapeutics, Inc.: Alladapt is reimagining the treatment of food allergy, developing a potentially best-in-class oral immunotherapy that addresses a broad range of food allergies. ADP101, which is currently in a Phase 1/2 clinical trial, is designed to desensitize patients allergic to one or to multiple foods simultaneously to mitigate the risk of severe, life-threatening allergic reactions. The company was co-founded by Dr. Kari Nadeau, a renowned food allergist, and former 23andMe exec, Ashley Dombkowski who serves as Alladapt’s CEO. To date, the company has raised $63 million from lead investor Gurnet Point Capital among other private investors. They expect data from the Harmony study, which is currently enrolling pediatric and adult patients, at the end of 2022.
Sector/Industry:
Healthcare
Characteristics:
Based in...
US - Pacific
Listing
Private
Address:
405 El Camino Real #611
Menlo Park, CA 94025
United States

Company Participants at Fall Private Company Showcase 2021

  • Ashley Dombkowski, CEO and Co-Founder

Upcoming Company Event Participation